Citigroup’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Hold
0
-$2 5857
2023
Q4
Hold
0
5664
2023
Q3
Hold
0
5637
2023
Q2
Hold
0
5533
2023
Q1
Hold
0
5430
2022
Q4
Hold
0
5732
2022
Q3
Hold
0
6324
2022
Q2
Hold
0
6666
2022
Q1
Hold
0
6602
2021
Q4
Hold
0
6093
2021
Q3
Hold
0
6302
2021
Q2
Hold
0
6404
2021
Q1
Hold
0
7368
2020
Q4
Hold
0
7633
2020
Q3
Hold
0
7604
2020
Q2
Hold
0
7679
2020
Q1
Hold
0
7779
2019
Q4
Hold
0
7806
2019
Q3
Hold
0
7824
2019
Q2
Hold
0
7858
2019
Q1
Hold
0
7812
2018
Q4
Hold
0
7837
2018
Q3
Hold
0
7869
2018
Q2
Hold
0
7740
2018
Q1
Hold
0
7676
2017
Q4
Sell
-3
Closed -$2.32K 7655
2017
Q3
$3K Hold
3
﹤0.01% 6969
2017
Q2
$3K Hold
3
﹤0.01% 6906
2017
Q1
$3K Hold
3
﹤0.01% 6943
2016
Q4
$3K Sell
3
-6
-67% -$6.2K ﹤0.01% 7029
2016
Q3
$17K Hold
9
﹤0.01% 6294
2016
Q2
$15K Sell
9
-1
-10% -$1.69K ﹤0.01% 6329
2016
Q1
$18K Hold
10
﹤0.01% 6598
2015
Q4
$16K Buy
10
+1
+11% +$1.77K ﹤0.01% 6604
2015
Q3
$15K Buy
9
+1
+13% +$2.41K ﹤0.01% 6219
2015
Q2
$22K Buy
8
+3
+60% +$7.79K ﹤0.01% 6052
2015
Q1
$14K Buy
5
+4
+400% +$11.1K ﹤0.01% 6293
2014
Q4
$2K Buy
+1
New +$2.58K ﹤0.01% 6878
2014
Q3
Sell
-1
Closed -$3.25K 6934
2014
Q2
$4K Buy
+1
New +$3.56K ﹤0.01% 6551
2014
Q1
Hold
0
7208
2013
Q4
Hold
0
7156
2013
Q3
Hold
0
6982
2013
Q2
Hold
0
6796

Other funds holding TRIB

Citigroup's TRIB Position: Q1 2024 in Review

Citigroup held its Trinity Biotech (TRIB) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5857.

Citigroup first reported a position in TRIB in Q2 2014 and has held it in 13 quarters since. The position peaked at $22K in Q2 2015. 19 funds tracked by Wall St. Rank hold TRIB as of Q1 2024.

  • Citigroup held 0 shares of Trinity Biotech worth $0 as of Q1 2024.
  • Citigroup left its Trinity Biotech share count unchanged in Q1 2024.
  • Trinity Biotech made up ﹤0.01% of Citigroup's portfolio in Q1 2024, its #5857 holding.
  • Citigroup first reported a position in Trinity Biotech in Q2 2014 and has held it in 13 quarters since.
  • Citigroup's Trinity Biotech position peaked at $22K in Q2 2015.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.